Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into ...

By Siddhi Mahatole June 8 (Reuters) - Incyte said on Monday it will buy Vega Therapeutics, a wholly owned subsidiary of ...

(Corrects paragraph 2 to say Hympavzi is the first non-factor therapy particularly for pediatric patients with hemophilia B, ...

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in ...

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...

Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing ...

(Family Features) Many people don’t think much about whether their blood is clotting properly. However, when you have a bleeding disorder, a condition that affects the way your body controls clots, it ...

A 75-year-old foundation updates its name to reflect a more comprehensive mission. The National Hemophilia Foundation (NHF) has changed its name to the National Bleeding Disorders Foundation (NBDF).

NATIONAL HARBOR, Md.--(BUSINESS WIRE)--The National Hemophilia Foundation (NHF) has officially changed its name to the National Bleeding Disorders Foundation (NBDF). Foundation leaders announced the ...

Bleeding Disorders affect more than three million Americans -- and plasma from human blood is often used for treatment. In observance of Bleeding Disorders Awareness Month, we are joined by Amber ...

Many people have a bleeding disorder and don't know it, but the Western Pennsylvania Bleeding Disorders Foundation is working to help people recognize the signs and get support. The foundation helps ...